The bulls continue to rage, as equity prices are up solidly across the board this Wednesday. Major healthcare, pharmaceutical, and financial stocks led the way for the broad-based rally, which left the Dow and other indexes well into all-time record territory.
Today’s top gainer managed to post gains even higher than the broader market. The pharmaceutical sector continues to feature prominently in our Top Performer reports. As valuations creep higher and higher, investors are desperate for signs of hidden value or growth potential. And growth potential can shift incredibly rapidly in the pharma sector, where a single product research news event can transform the valuation of an entire company.
This morning, AEZS announced a new licensing agreement Stonebridge Pharma. Under this agreement, Aeterna Zentaris will conduct the final development, manufacturing, and commercialization for Macrilen, a new drug developed by Stonebridge.
AEZS will be paid $24 million upfront per the terms of the agreement and will garner substantial 15%+ royalties on Macrilen sales. The agreement covers commercialization rights for the US and Canada. AEZS will also receive payments for a series of commercialization milestones as they are completed.
Macrilen is an orally ingested treatment designed to treat Growth Hormone Deficiency. Adequate levels of growth hormone are essential not only for normal childhood growth and development but well-balanced hormone levels as an adult.
Investors bought AEZS heavily on the news, driving the stock to gains over 20% a the time of this writing. NewsQuantified users have managed to profit on the development of Macrilen multiple times.
In June, 2017 we featured AEZS on our Top Performers blog—it posted 40% gains on news that the US FDA hasd accepted their application for Macrilen approval. Then, this past December, we featured AEZS again—it posted 40% plus gains on news of FDA approval. Today's gains provide a cherry on top of massive successive news-based trading gains on a single product from a single industry.
Diverse Plays, Great Profits: All in a single news day.
Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!
We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.
Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock
A powerful news analytics platform like NewsQuantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.
How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like NewsQuantified? Let us know in the comments below.